Ny forskning fra Cleveland Clinic viser for første gang, at FDA-godkendt ibrutinib (ibrutinib) til lymfom og leukæmi også kan hjælpe med at behandle de mest almindelige og dødelige hjernetumorer, og en dag kan blive brugt til patienter med glioblastom og forbedre overlevelsesraterne.
Ifølge rapporten fra American Brain Tumor Association er overlevelsesraten for glioblastom meget lav, og medianoverlevelsen for patienter, der modtager standardbehandling, er mindre end 15 måneder. Glioblastom er den mest dødelige primære hjernetumor og er meget modstandsdygtig over for nuværende behandlinger. Der er et presserende behov for at give disse patienter nye behandlinger så hurtigt som muligt.
In an earlier study, Bao and colleagues found that gliom stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tumorer in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
